Cardiogenic shock continues to portend poor outcomes, conferring short-term mortality rates of 30% to 50% despite recent scientific advances. Age is a nonmodifiable risk factor for mortality in patients with cardiogenic shock and is often considered in the decision-making process for eligibility for various therapies. Older adults have been largely excluded from analyses of therapeutic options in patients with cardiogenic shock. As a result, despite the association of advanced age with worse outcomes, focused strategies in the assessment and management of cardiogenic shock in this high-risk and growing population are lacking. Individual programs oftentimes develop upper age limits for various interventional strategies for their patients, including heart transplantation and durable left ventricular assist devices. However, age as a lone parameter should not be used to guide individual patient management decisions in cardiogenic shock. In the assessment of risk in older adults with cardiogenic shock, a comprehensive, interdisciplinary approach is central to developing best practices. In this American Heart Association scientific statement, we aim to summarize our contemporary understanding of the epidemiology, risk assessment, and in-hospital approach to management of cardiogenic shock, with a unique focus on older adults.

中文翻译：

---

老年人心源性休克：关注与年龄相关的风险和管理方法：美国心脏协会的科学声明

尽管最近的科学进步，心源性休克仍然预示着不良后果，导致短期死亡率高达 30% 至 50%。年龄是心源性休克患者死亡的不可改变的危险因素，在决定是否适合接受各种治疗的决策过程中通常会考虑年龄。老年人基本上被排除在心源性休克患者治疗选择的分析之外。因此，尽管高龄与较差的结果相关，但在这一高危且不断增长的人群中，缺乏评估和管理心源性休克的针对性策略。个别项目通常会为其患者制定各种介入策略的年龄上限，包括心脏移植和耐用的左心室辅助装置。然而，年龄作为一个单独的参数不应被用来指导心源性休克的个体患者管理决策。在评估老年人心源性休克的风险时，综合性、跨学科的方法对于制定最佳实践至关重要。在这份美国心脏协会的科学声明中，我们旨在总结我们对流行病学、风险评估和院内心源性休克治疗方法的当代理解，特别关注老年人。